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Objective: We plan to review the current problem of lean mass erosion in catabolic
states, caused by injury and critical illness. This protein loss is driven by the hormonal
imbalanceandexcessinflammationreferredtoasthe“stressresponsetoinjury.”Wethen
plantoprovidethecurrentconceptsontheuseofavailableanabolicagentstoattenuatethe
excess catabolism. Data Source: The available published literature on the pathogenesis
ofacutecatabolicstatesandtheuseofanabolicandanticatabolicagents,theirindications,
mechanism of action, and potential complications was reviewed. Data Extraction: The
current understanding and experience of the available anabolic and anticatabolic agents
as well as the rationale for the use of each anabolic agent are described. Conclusion: We
concludethatthepreservationofleanbodymass(bodyprotein)isextremelyimportantin
the management of critical care populations, as lean mass loss leads to severe morbidity
andincreasedmortality.Essentially,alloftheavailableanabolicagentsstimulateprotein
synthesis and decrease protein breakdown, but all have different mechanisms of action.
Adequate nutrition, especially protein intake, is essential for any anabolism to occur.
Combined anabolic therapy also appears to be advantageous. Although controlling the
inflammatoryresponsewouldalsobeofmajorbenefitinfurthercontrollingproteinloss,
effective and safe anti-inflammatory agents have not yet become clinically available for
this purpose.
There is a very complex relationship between hormones, nutrition and protein synthe-
sis, anabolism, or protein degradation. This is severely disrupted with bodily stress. The
stress response to injury, including surgery or any significant illness, can be considered
to be a maladaptive or autodestructive process.1–3 The body consumes itself, especially
muscle, for energy instead of using body fat. This process is the result of an excessive
catabolic activity due to both a hormonal imbalance and excess inflammation.1–5 A loss of
lean body mass occurs, with the degree of loss corresponding with subsequent mortality
and morbidity.
The initiating event, known as the “fright-flight” response, was added to the human
genome thousands of years ago as a way of generating a surge of energy to deal with
a short-term threat or injury.1 Since very little glucose, which is the primary source of
immediate energy, is stored in the body, the most rapid source of energy is the components
in body protein, namely, amino acids, which can be converted to glucose or used directly
for energy.1–4
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Table 1. Metabolic abnormalities due to the “stress response” of injury
• Increase in levels of catabolic hormones (cortisol and catechols)
• Decrease in levels of anabolic hormones (human growth hormone and testosterone)
• Increase in levels of proinflammatory cytokines
• Decrease in levels of anti-inflammatory cytokines
• Increase in acute-phase protein production
• Marked increase in metabolic rate (with increased energy initialization)
• Sustained increase in body temperature
• Rapid skeletal muscle breakdown with amino acid use for both energy source and gluconeogenesis
• Insulin resistance, resulting in an increase in blood glucose levels
• Unresponsiveness of catabolism to nutrient intake (feeding)
This response is activated immediately after a stress insult and peaks around 3 to 5
days postinsult. An inevitable loss of muscle and body protein occurs, which is deleterious
to all bodily functions.1–7 Unfortunately, this catabolic process cannot be turned off until
the injury or illness has resolved itself totally, even if adequate glucose is provided.1–3
The magnitude of this autodestructive response is in large part dependent upon the
magnitude of the insult and the time course to complete recovery. The impact on the patient
can be extremely harmful and can even prove fatal. So how can this process be controlled?
It is now well recognized that providing certain anabolic agents can help neutral-
ize the net catabolism and restore hormonal balance in the stressed patient population,
thereby significantly decreasing the catabolic response to “stress.”8,9 However, the degree
of inflammation, which is also catabolic, has not yet been effectively altered with the possi-
ble exception of the anabolic hormone insulin-like growth factor-1 (IGF-1)/IGF-1-binding
protein-3 (IGFBP-3).5–7
THE STRESS RESPONSE TO INJURY OR ILLNESS
Essentially,anysignificantinjuryorillnesswillactivatethecatabolic“stressresponse,”10–12
and the outcome of any catabolic state is strongly influenced by the degree of net protein
breakdown compared with the amount of net protein production or anabolism.13–16 This
balance or imbalance will be determined by the magnitude and longevity of the catabolic
state and the therapeutic modalities initiated to control this response. The metabolic abnor-
malities produced are fairly well described in Table 1.
Thestressresponseischaracterizedbyincreasedandprotractedlevelsofthehormones
epinephrineandcortisol,whichincreaseenergydemandsbeyondneedsandcauseincreased
protein breakdown, primarily for the production of excess glucose and for energy.11–12
In addition, levels of endogenous anabolic hormones, human growth hormone (HGH),
and testosterone are decreased. The level of IGF also goes down, leading to a state of
insulinresistance,insulinalsobeingananabolichormone.1–4,14–16 Thisabnormalhormonal
environment leads to a net increase in catabolism or protein degradation of muscle and
visceral protein (Table 2).14–20
Inflammation, a component of any injury or infection, generates products,
such as proinflammatory cytokines and oxidants, that will produce further protein
degradation.5–7,15–25 Also, the production of important proteins, required for normal
metabolism by the liver, is decreased in favor of what are known as “acute phase proteins,”
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Table 2. Actions of key hormones in metabolism
Catechols Cortisol Insulin Human growth hormone Testosterone
Gluconeogenesis ↑ ↑ ↑ ↑ ···
Glycogen formation ↓ ↓ ↓ ↓ ···
Glycogenolysis ↑ ↑ ↓ ↑ ···
Lipogenesis ↓↑ ↑ ↓ ↓
Lipolysis ↑↓ ↓ ↑ ↑
Ketone production ↓ ↓ ↓ ↑ ···
Protein synthesis ↑↓ ↑ ↑ ↑ ↑
Proteolysis ↑↑ ↓ ↓ ↓
which are primitive proteins with immune properties. The degree of acute-phase protein
production typically corresponds with the magnitude of the inflammatory response.26–28
CHANGES IN LEAN BODY MASS WITH A CATABOLIC STIMULUS
Theleanbodymasscontainsalltheproteinspresentinthebodyaswellasallthewater.Two
thirds of the protein is found in muscle and skin. The remainder is responsible for organ
structure and function, immunity, enzyme activity, and any new tissue formation.29–32
As opposed to fat mass, which is basically a storage depot for available calories,
there are no stored proteins; all have some significant physiological or metabolic function.
Therefore, any net protein loss is harmful.28–33
Protein,insteadoffat,becomesamajorfuelsourcewith“stress,”asseeninstarvation,
because of the abnormal hormonal and inflammatory environment. Breaking down protein
overthelong-termismaladaptiveandautodestructive.20–23 Proteinisalsoaverypoorsource
of calories, generating only 4 calories per gram, yet breakdown of protein makes up more
than 30% of the calories used after an injury or after any significant body insult. Loss of
lean mass instead of fat will lead to significant complications (Table 3).
The complications of lean mass loss correspond to the amount and rate of lean body
mass loss relative to total, assuming total to be not compromised.30,33
Aleanbodymasslossof10%,whichisquitecommonwithcriticalillness,corresponds
to increased complications.30–33 Protein loss will increase infection risk, which may prove
fatal. With a large protein loss, 30% or greater, spontaneous wounds develop as loss of
protein from the skin leads to skin breakdown with pressure. A loss of more than 40% of
Table 3. Hormonal response to stress and starvation∗
Starvation Stress
Catechols ↓↑ ↑
Cortisol ↓↑ ↑
Insulin ↓↑
Glucagon ↓↑
Human growth hormone ↑↑ ↓
Testosterone ↓↓
∗With starvation, an adaptive hormonal response is present, preserving lean mass and energy, while
a maladaptive catabolic state occurs with the “stress response” activated by any wound.12,31
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Table 4. Complications relative to loss of lean body mass
Lean body mass,∗
% loss of total Complications (related to lost lean mass) Associated
10 Impaired immunity, increase in infection 10
20 Decrease in healing, weakness, infection 30
30 Too weak to sit, pressure sores, pneumonia, no healing 50
40 Death, usually from pneumonia 100
∗The complications correspond with the degree of loss relative to total lean body mass, assume no
preexisting loss as is often present especially in the elderly.
lean body mass is typically fatal as it leads to cell shutdown, which cannot be reversed
(Table 4).30–33
It is also important to recognize that the restoration of body protein is at least 4-
fold slower than the rate of loss although the use of anabolic agents can accelerate this
restoration.2,34–40
ANABOLIC AND ANTICATABOLIC AGENTS
It is now clear that controlling the catabolic state, by increasing anabolism and controlling
inflammation, is essential to improving the outcome and decreasing complications in the
severely injured and critical ill population. Therefore, the main frontier in critical care is to
control both the excess protein loss from hormonal imbalance and the organ damage from
inflammation.19–25 Controllingtheinjurystateorillnessis,ofcourse,paramount.Providing
optimum nutritional support is also essential to keep up with the increased energy (caloric)
and protein demands as well as the increased intake of micronutrients. Typical required
protein intake per day is 1.5 g/kg.24,25
The purpose of this review, however, is to focus on anabolic agents that can assist in
controlling protein loss. Controlling the inflammatory response is something that is yet to
be achieved.21–26
A number of anabolic and anticatabolic strategies are now available for clinical use.
Several of these agents have been shown to be remarkably effective.34–41 Like any new
treatment modality, the objective is to utilize the most effective agent or a combination
of anabolic-anticatabolic agents with the fewest side effects. Either effect is recognized to
be beneficial. Many of the anabolic agents also have anticatabolic properties, often due to
down-regulation of cell cortisol receptors.34–41
In general, these agents are either amino acids or metabolites that stimulate protein
synthesis or hormones with anabolic activity. All of the agents, currently available, have a
specificmechanismofactioneitherasasubstrateorasanactivatorofspecificcellfunctions,
namely, protein synthesis (Table 5). Sufficient protein intake is essential to support any
anabolic activity.
It is important to point out that none of the currently used anabolic agents have an
effect on the important inflammatory catabolic component of the stress response with the
possible exception of the compound IGF-1/IGF-BP3 (Table 6).
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Table 5. Available anabolic agents
Amino acids or metabolites
Glutamine
Arginine
Hydroxy methyl butyrate
Anabolic hormones
Insulin
Insulin-like growth factor-1 (IGF-1)
IGF-1 with IGFBP-3∗
Testosterone
Anabolic steroids
Human growth hormone
∗IGF-1 bound to IGF-1-binding protein 3.
AMINO ACID THERAPY
Specific amino acid therapy can lead to an increase in protein synthesis; however, there are
no recognized effects on inflammation.42–44
Glutamine
Glutamineisthemaincarrierofnitrogenbetweenvarioustissues,includingskeletalmuscle,
liver, intestines, and kidney. The liver uses glutamine as a preferred source of energy.
Glutamine is also a precursor, along with cysteine, for the key intracellular antioxidant
glutathione, which is produced in the liver and then exported to other organs, especially the
lung. Enterocytes prefer to use glutamine instead of glucose as their primary energy source.
Theavailabilityofglutamineisnowrecognizedasarate-limitingstepinmuscleprotein
synthesis, and the rate of protein turnover in muscle depends in part on the availability
of glutamine. In addition, there is a well-recognized glutamine deficiency state within
48 hours of a severe injury or illness and glutamine then becomes an essential amino
acid. Increasing glutamine intake appears to have both anticatabolic and anabolic effects.
Glutaminesupplementationatthelevelof0.5mg/kgperdayhasbeenshowntosignificantly
Table 6. Effects of available anabolic agents
Agent Anabolic Anticatabolic Inﬂammation Blood glucose
Glutamine ↑↑ ... ...
Arginine ↑ ... ... ...
Hydroxy methyl butyrate ... ↑ ... ...
Insulin ↑↑ ... ↓
Insulin-like growth factor-1 (IGF-1) ↑↑ ... ↓
IGF-1 plus IGFBP-3∗ ↑↑ ↓ Maintains
Testosterone ↑↑ ... ...
Oxandrolone ↑↑ ... ...
Human growth hormone† ↑↑ ... ↑
∗IGF-1 bound to IGF-1-binding protein 3.
†Human growth hormone +β-hydroxy methyl butyrate.
37JOURNAL OF BURNS AND WOUNDS VOLUME 6
Table 7. Metabolic effects of glutamine
• A deficiency state occurs with “stress”
• Primary nutrient source for gut mucosa
• Precursor of glutathione (antioxidant)
• Anticatabolic activity at the muscle cell level
• Anabolic activity with supplementation at 0.5 mg/kg per day
• Improves nitrogen retention
• Stimulates human growth hormone release (anabolic activity)
• Decreases infection rates
• Improves survival after severe injury
• Increases ammonia in liver failure
decrease mortality rates in major burn injury, significantly decrease infection rates, and
increase protein synthesis in other high-risk critically ill populations45–47 (Table 7).
The major anabolic and anticatabolic property of glutamine is likely because of in-
creasedavailabilityforproteinsynthesisinapostinjurydeficiencystate.Anotherpotentially
important anabolic action of glutamine is stimulating HGH release.44–49 The mechanism
forthisactionremainsunknown.Thereisnotyetaunanimousopinionastowhichcritically
ill patient populations benefit from glutamine supplementation. Certainly, it is effective in
trauma patients but the effect is less clear in patients with sepsis.
Ornithine α-ketoglutatrate (OKG), a precursor of glutamine, is also reported to have
anabolic activity. The mechanism of action of OKG is not clearly understood, but it appears
to act by the enhanced secretion of anabolic hormones and the increased synthesis of
metabolites, glutamine, polyamines, and arginine.
Itisrecommendedthathigh-doseglutaminenotbegiveninthepresenceofliverfailure
due to increased production of ammonia.
Arginine
Arginine has been shown to have a wide variety of potentially beneficial metabolic effects
in the injured or critically ill patient population. The most important pathway of arginine
metabolism appears to be its conversion to orthinine in the liver, which is an obligatory
precursor for protein synthesis (Table 8).50–52
Argininesupplementation,usuallyupto20g/d,hasbeenreportedtoreduceweightloss
andnitrogenlossandimprovenitrogenretentionandwoundhealing.50–52Themechanismfor
thisactionisunclear.OnemechanismmaybestimulationofthereleaseofHGH.Inaddition,
there is clearly an increase in lymphocyte production and therefore an immune system
stimulationeffect.Improvedwoundhealing,asevidencedbyincreasedcollagendeposition,
has also been well described in experimental studies. Clinical data on healing or infection
Table 8. Metabolic effects of arginine
• Levels decrease with “stress”
• Increases nitric oxide production
• Reduces nitrogen loss
• Reduces weight loss
• Stimulates lymphocyte activity
• May stimulate release of human growth hormone
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controlismuchlessconvincing.50–52 Apossiblecomplicationofhigh-dosereplacementmay
be increased production of nitric oxide, which has been reported to have both deleterious
and beneficial effects. There are no studies on the advantages or disadvantages of arginine
supplementation in critical illness at the present time, although there are a number of
important products on the market with increased arginine content. More clinical studies,
verifying the efficacy of arginine as an anabolic agent other than increased wound collagen
deposition, still need to be performed.
Hydroxy methyl butyrate
β-Hydroxymethylbutyrate(HMB)isametaboliteoftheessentialaminoacidleucine.Ithas
been shown, in a number of clinical trials, to decrease catabolism in normal man and in the
elderly after exercise. The mechanism of action appears to be related to the fact that leucine
depletion, during stress, increases catabolism and providing the HMB metabolism, blocks
this response. In addition, HMB has been shown, in several clinical trials, to increase the
restoration of lean mass in conjunction with exercise, felt to be the result of its anticatabolic
effect.53–55 HMBisavailableforclinicaluseasapowder,withtherecommendeddosebeing
1.5 g every 12 hours.
Combined amino acids
Glutamine, arginine, and HMB were combined in a nutritional supplement (JUVEN) that
showed a decrease in catabolism and an increase in lean mass in catabolic states (HIV ,
cancer, and elderly weight loss) in 3 randomized controlled studies.56,57 It is important to
note that all 3 components work through different metabolic pathways. However, the role
of each amino acid in the anabolic actions of the combined product is not known.
ANABOLIC HORMONE THERAPY
Insulin
Insulinisanaturallyoccurringendogenouspolypeptidehormonebestknownforcontrolling
blood glucose levels by increasing glucose uptake at the cell level. Insulin also has potent
anabolic and anticatabolic properties and has been shown in a number of trials to increase
protein synthesis, especially when given in increased concentration to burn and trauma
patients (Table 9).58–66
Its mechanism of action is complex but mainly involves transport of amino acids,
glucose, and fat into the cell while decreasing the efflux of amino acids from the cell.61
Table 9. Metabolic effects of insulin
• Endogenous anabolic hormone
• Activity decreased with “stress”
• Increases transport of amino acid into cells
• Decreases loss of amino acid from cells
• Stimulates protein synthesis in catabolic states
• Decreases protein breakdown in catabolic states
• Excess amounts can lead to hypoglycemia
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Table 10. Metabolic effects of insulin-like growth factor-1
• Endogenous anabolic hormone
• Levels decrease with “stress response”
• Production by many cells, especially in the liver
• Production dependent on adequate levels of human growth hormone
• Actions much like those of insulin
• Increases protein synthesis
• Known to directly stimulate wound healing
• Extremely short half-life when binding protein is not attached
• Can produce problematic hypoglycemia
• Requires continuous infusion with monitoring of glucose levels
• Decreased efficacy with long-term infusion
Its anticatabolic effect relates to a decrease in proteolyses. The anabolic activity is
mainly seen in the protein content of muscle and skin in the lean mass compartment. The
anabolic response to insulin decreases with aging while most other anabolic agent activity
isnotagerelated.Increasedre-epithelializationofskingraftdonorsiteswasreportedinone
clinical trial in burn patients. Several animal studies have demonstrated increased collagen
productionwithinsulinandincreasingthelevelofinsulinadministeredtomicewithdiabetes
improved all phases of healing. However, the effects of insulin on wound healing have not
been well studied in man.
The major complication with its use as an anabolic agent is hypoglycemia, requiring
rigorous monitoring of glucose levels. Also, because of its short half-life, a continuous
parenteral insulin infusion is especially utilized. There are no recognized effects of insulin
on the inflammatory phase of the stress response. Insulin will also cause fat production in
liver if excess glucose is also present.
Insulin-like growth factor-1
IGF-1 is a naturally occurring large polypeptide that has hormone-like properties. IGF-1,
also known as somatomedin-C, has metabolic and anabolic properties very similar to those
of insulin (Table 10).67–72
IGF-1 is produced by a variety of wound cells, such as fibroblasts and platelets. The
main source of production is the liver where IGF synthesis is initiated by HGH. The IGF
receptor on the cells is expressed in many different tissues and active peptide is bound, in
plasma,byIGF-bindingproteins.Itsproductionisdecreasedin“stress,”especiallysepsis.67
Anabolic activity is noted when IGF-1 is provided by continuous infusion.68–72 However,
the response is difficult to separate from that of increases in endogenous insulin or HGH.
Therearenoclinicalstudiesshowinganti-inflammatoryactivitywithIGF-1.Also,anIGF-1
infusion loses its anabolic activity with long-term use.
The attenuation of stress-induced hypermetabolism is a favorable property of IGF-1.
TheclinicaltrialsusinganIGF-1infusionhavefocusedondemonstratingincreasedanabolic
activity. Increased protein synthesis and nitrogen retention has been reported in burns, head
injury, and HIV-induced catabolic states.
The major problem with its use is the risk of hypoglycemia (low glucose). Also prob-
lematic is the need for a continuous intravenous infusion, requiring that glucose levels be
monitored.Low-doseinfusionsarenoteffective.Theidealdosehasnotyetbeendetermined.
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Table 11. Metabolic effects of IGF-1/IGFBP-3
• Endogenous anabolic hormone
• Levels decrease with injury/infection/stress
• Production directly correlated with human growth hormone levels
• Increases protein synthesis (anabolism)
• Decreases protein breakdown (catabolism)
• Attenuates proinflammatory response
• Attenuates the acute phase response to “stress”
• Improves production of essential proteins by the liver
• Improves organ function in a catabolic state
• Maintains normal glucose
Insulin-like growth factor-1 bound to IGF-1-binding protein-3
BindingofIGF-1toitsmajorbindingproteinIGFBP-3resultsinnewandveryadvantageous
properties compared to those of IGF-1 alone (Table 11).
As expected, many properties remain similar to those of IGF-1 and insulin. However,
the half-life is increased from minutes to more than 12 hours. Exogenous IGF infusion,
over time, appears to lead to an attenuation of its anabolic effects. This attenuation is
not seen with the exogenous administration of the IGF-1/IGFBP-3 complex. There is a
significant increase in protein synthesis (anabolism) and anticatabolic properties persist
and remain constant with long-term administration. Interestingly, the anabolic effects of
IGF-1/IGFBP-3 increase as the catabolic stimulus increases. Increased wound healing has
also been demonstrated, much like that for IGF-1.73–80
Of major importance is the effect of this hormone and protein complex on excess in-
flammation,animportantcomponentofthe“stress”catabolicresponse.IGF-1/IGFBP-3has
been shown in burn patients, who have a profound catabolic and the systemic inflammatory
response, to decrease the magnitude of both catabolism and inflammation.77–80 This effect
wasidentifiedbyadecreaseinthelevelsofproteinproductsintheacutephase.77–80 Levelsof
important proteins, normally suppressed, such as prealbumin and albumin, were increased.
Inaddition,therewasadecreaseinproinflammatorycytokines,whichareactivatorsof
inflammation,resultinginabetterbalancebetweenproinflammatoryandanti-inflammatory
cytokines.Remarkably,butnotunexpectedly,thisattenuationoftheinflammatoryresponse
corresponds with improved cardiac, liver, and renal function.80 It would be anticipated that
attenuation of inflammation would improve organ function as organ failure is the typical
response to autodestructive inflammation.23–29 Organ failure is a major cause of mortality
in severe catabolic states.23–29,79
The other beneficial effect of this complex as opposed to other anabolic agents is
its effect on normalizing blood glucose levels. Both low and high blood glucose levels,
seen with the use of some other anabolic agents, have been well documented to be very
deleterious.73–80
Testosterone
Testosterone, whose basic structure is a steroid ring, is the natural endogenous androgen.
Testosteroneissynthesizedprimarilyinthetesticlesinmalesandbytheovariesandadrenal
gland in females. Testosterone acts on the cells’ androgenic receptors found mainly in skin,
muscle, and male sex glands.
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Table 12. Metabolic effects of testosterone
• Endogenous anabolic hormone
• Levels decrease with “stress” response
• Modest anabolic activity compared to that of its analogs
• Rapidly metabolized by the liver
• Levels decrease with increasing age
• Decreased levels of testosterone cause lean mass loss
• No effects on glucose metabolism
• Androgenic (masculinizing) side effects include male sex gland development, male pattern of hair,
and mood
It has both androgenic and masculinizing properties and anabolic or protein synthesis
properties (Table 12). The importance of testosterone is evidenced by the complications
seen with low testosterone level, which include sarcopenia or lost lean mass, increased rate
of development of osteoporosis, anemia, thinning of skin, impaired wound healing, and
weakness (Table 13).81–86
Testosterone levels decrease with any severe stress. Testosterone replacement is essen-
tial in hypogonadal states to avoid further lean mass loss and the other complications of low
testosterone levels. Replacement is typically done by depot injection.
However,beyondreplacementtherapy,testosteroneisnotusedasananabolicagentasit
has relatively weak anabolic activity compared to its analogs and its androgenic side effects
can become problematic.82,83 Testosterone has no effect on the inflammatory process or on
glucose metabolism. The major complications with its use are a decrease in high-density
lipoproteins, some fluid retention, and endrogenic effects.
Oxandrolone (testosterone analog)
Anabolic steroids refer to the class of drugs produced by modification of testosterone.85–93
These drugs were developed in order to take clinical advantage of the anabolic effects of
testosteronewhiledecreasingtheandrogenicsideeffectofthenaturallyoccurringmolecule.
Modifications were made in the steroid ring because of the short half-life of testosterone
and its masculinizing properties. Modifications included a 17-α-methyl derivative for oral
use and a 17-ß-ester configuration for parenteral use. These changes markedly increased its
half-life and decreased its androgenic properties.
The mechanisms of action of testosterone analogs are also through activation of the
androgenicreceptorsfoundinhighestconcentrationinmyocytesandskinfibroblasts.Some
Table 13. Effect of decreased levels of testosterone (the
hypogonadal state)
• Lean mass loss
• Thinning of skin
• Increase in fat mass
• Impaired wound healing
• Decrease in physical and psychological masculinizing properties
• Osteoporosis
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Table 14. Anabolic activity of 17 methyl derivatives
Androgenic:
Agent Anabolic activity Indication Hepatoxicity
Testosterone 1:1 Hypogonadism
Nandrolone 1:4 Anemia Moderate to severe
Oxymetholone 1:3 Anemia Severe
Oxandrolone∗ 1:16 Loss of body weight from injury
or infection
Mild, rare
∗The anabolic steroid oxandrolone is the only approved drug for restoration of lost body weight and lost lean mass.
populations of epithelial cells also contain these receptors. Androgenic receptors were first
isolated in the 1960s.
Stimulation of these receptors leads to a decrease in the efflux of amino acids and an
increase in the influx into the cell. Activation of intracellular DNA and DNA polymerase
alsooccurswithandrogenicreceptorstimulation.Adecreaseinfatmassisalsoseenbecause
of the preferential use of fat for fuel. There are no metabolic effects on glucose production.
All anabolic steroids increase overall protein synthesis and new tissue formation, as
evidenced by an increase in skin thickness and muscle formation. All these agents also
have anticatabolic activity, decreasing the protein degradation caused by cortisol and other
catabolicstimuli.1 Inaddition,allanabolicsteroidshaveandrogenicormasculinizingeffects
(Table 14).
Oxandrolone is a synthetic anabolic steroid with potent anabolic and anticatabolic
activitywithminimalandrogenic(masculinizing)properties.85–93Itactsoncells’androgenic
receptors, found mainly in the lean mass compartment, to increase protein synthesis.
Oxandrolone, a modified form of testosterone, is the only FDA-approved anabolic
steroid used for restoring lost body weight. The safety advantage of oxandrolone is that it
is cleared by the kidney rather than the liver so hepatoxicity, which is a major problem with
other anabolic steroids, is less of an issue. Its anabolic activity is approximately 10 times
that of testosterone and its androgenic activity is one tenth that of testosterone. Currently,
this agent is being used clinically not only to restore lost lean mass but also to preserve lean
mass loss in catabolic states. Its half-life is 9 to 12 hours. Oxandrolone is given orally twice
a day, usually 10 mg per dose. It has been shown to decrease net catabolism in a number of
catabolic states, burns being the most significant. Anabolism is increased in both the acute
state and during the recovery period (Table 15).
Table 15. Metabolic effects of oxandrolone
• Testosterone analog
• Stimulates protein synthesis only in the lean mass compartment
• No effect on glucose metabolism
• Increases use of fat for fuel
• Marked attenuation of catabolism
• Increases anabolic activity
• Rapid restoration of lean body mass
• Cannot be used in the presence of an androgenic tumor
• Increases coumadin sensitivity
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Testosterone analogs act only on androgenic receptors found only in the lean body
mass compartment.85 There are no effects on metabolism other than protein synthesis.
Testosterone analogs cannot be used in the presence of androgenically sensitive85 tumors,
whichincludeprostatecancerandmalebreastcancer.Oxandrolonealsoincreasessensitivity
to Coumandin, necessitating adjustment in its dosage.
Studies indicate that anabolic activity is markedly increased in injured men, elderly
with and without wounds, steroid-dependent patients, cachexia, HIV , chronic obstructive
pulmonary disorder, and cancer chemotherapy with weight loss.87–93 Adequate protein in-
take is required.
Human growth hormone
HGHisapotentendogenousanabolichormonethatisalsoanticatabolic,actingonaspecific
HGH cell receptor. HGH is a large polypeptide with a number of binding proteins and cell-
binding sites. Starvation and intensive exercise increase HGH production. Severe, acute, or
chronic illness decreases HGH levels.94,95
Clinical studies have in large part focused on the systemic anabolic and anticatabolic
actions of HGH. Populations in which HGH has been shown to have beneficial effects
include those with severe burn and trauma, those with HIV infection with wasting, and frail
elderly adults. In addition, HGH is being used to slow down the aging process. Increase
in lean mass, muscle strength, and immune function has been documented in clinical use.
HGH is approved only for use in children of short stature and is an orphan drug when
used for improving protein synthesis. Increased anabolic activity requires ingestion of a
high-protein, high-energy diet.96–100
As to any direct wound healing effects, skin is a target tissue for HGH, both directly
throughHGHreceptorsonthesurfaceoftheepidermalcellsandindirectlythroughtheaction
of IGF-1. Exogenously administered HGH has been shown to increase skin thickness in
normal humans.48 Other effects on the wound include increased rate of re-epithelialization
of skin graft donor sites in adults and children with severe burns or trauma (Table 16). In
addition, HGH has been shown to increase wound collagen content, granulation tissue and
wound tensile strength, and the local production of IGF-1 by fibroblasts. These data are
derived mainly from animal studies.
Table 16. Metabolic effects of human growth hormone
• Endogenous anabolic hormone
• Decreased production with “stress”
• Increases cell uptake of amino acids
• Increases protein synthesis (anabolism)
• Decreases catabolism
• Increases release of insulin-like growth factor-1
• Increases insulin requirements
• Increases use of fat for fuel
• Increases metabolic rate (10%–15%)
• Produces insulin resistance, often leading to hyperglycemia
• May increase mortality in subpopulations of critically ill patients
• No anti-inflammatory effects
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HGH when provided typically binds with one of its binding proteins. HGH has a
number of metabolic effects, the most prominent being its anabolic activity but insulin
resistance also occurs, which often leads to hyperglycemia, which will increase morbid-
ity. A positive metabolic response is the increased use of fat for fuel. Another negative
effect is the increase in metabolic rate (10%–15%), which occurs with the typical dose of
HGH (10 mg twice a day in an adult) or 0.2 to 0.3 mg/kg per day. HGH must be given
parenterally.
HGH has been used in the clinical setting for at least 25 years for its anabolic and anti-
catabolic activity.96–100 Recently, evidence has come up that HGH can be harmful to certain
critical care populations.101,102 This is likely the result of the inevitable hyperglycemia,
which has now been shown to markedly increase morbidity and mortality in the critically
ill.Inaddition,theincreaseinmetabolicratecanbedeleteriousinanalreadyhypermetabolic
patient.101,102
CONCLUSION
The“stress”or“fright-flight”responseoccurswithanysignificantinjury,includingsurgery,
infections, or critical illness. This genetically programmed response, which may have been
beneficial for short-term insults, has become maladaptive and autodestructive in modern
man because of the longer time course and more severe insults, which are managed today
with modern medicine.
This response is a combination of an abnormal hormonal imbalance and excessive
injury/insult-induced inflammation. Increase in the levels of catabolic hormones (cortisol
and epinephrine) and decrease in the levels of anabolic hormones (HGH and testosterone)
leads to increased protein breakdown and decreased protein synthesis.
Inaddition,inflammation,drivenbyexcessiveproinflammatorycytokines,alsocauses
catabolism (protein breakdown), resulting in infections, organ damage, and death.
Managing the catabolic, hormonal, and excessive inflammatory state is becoming
a primary focus of new advances in critical care. There are a number of anabolic and
anticatabolic agents currently being used, in critical care, that have beneficial properties, by
improvingoverallnetanabolism.Itisclearthatalltheseagentsareeffectiveinthecatabolic
states of injury and illness.
The anabolic amino acids glutamine, arginine, and HMB all have significant anabolic
and anticatabolic activity. Glutamine clearly has the most potent properties.
The anabolic hormones currently available include insulin, IGF-1, and IGF-1/IGFBP-
3, which is IGF-1 bound to the IGF-1-binding protein 3, testosterone and its analogs, and
HGH.
Theanabolicaminoacidsarequitesafeanddoincreaseanabolisminstressstates.There
are also a number of anabolic and anticatabolic hormones being used. All of them decrease
but do not eliminate catabolism. The reason is that inflammation is not controlled. Of in-
terest is the finding that the anabolic agent IGF-1/IGFBP-3 appears to not only increase
anabolism but also decrease the inflammatory response. In addition, glucose dysregula-
tion is not seen. Hypoglycemia and hyperglycemia are also seen with insulin, IFG-1, and
HGH, respectively. This problem can be controlled with adequate monitoring of glucose
levels.
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Overall, current clinical data would indicate that anabolic therapy can be safely in-
tegrated into the management of severe injury and critical illness and should result in
improvement in outcome.
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